First human test for fatty liver pill shows path forward

This early-stage study tested a new oral drug called J2H-1702, which is being developed to treat non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to check the drug's safety, how the body processes it, and how well it was tolerated in 100 healthy male volunteers. Researchers gave different doses to groups of participants, comparing the drug to a placebo, to find a safe dose range for future studies in patients.